¹Ì±¹ÀÇ DBS(Dried Blood Spot) äÃë Ä«µå ½ÃÀå - ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : ¿ëµµº°, Ä«µå À¯Çüº°, ÃÖÁ¾ ¿ëµµº°, ³ª¶óº°, ºÎ¹® ¿¹Ãø(2024-2030³â)
U.S. Dried Blood Spot Collection Cards Market Size, Share & Trends Analysis Report By Application (New Born Screening (NBS), Forensics), By Card Type (Whatman 903, FTA), By End-use, By Country, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå
:
1493239
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2024³â 05¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 70 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¹Ì±¹ÀÇ DBS(Dried Blood Spot) äÃë Ä«µå ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é ¹Ì±¹ÀÇ DBS äÃë Ä«µå ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 1¾ï 4,990¸¸ ´Þ·¯¿¡ À̸£°í, ¿¹Ãø ±â°£ µ¿¾È CAGR 3.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
½Å»ý¾Æ ½ºÅ©¸®´×ÀÇ ¿ëµµ Áõ°¡¿Í ¹ýÀÇÇÐ µ¶¹°Çп¡¼ DBS Ä«µåÀÇ »ç¿ë È®´ë´Â ½ÃÀå ¼ºÀåÀÇ Áß¿äÇÑ ¿ä¼ÒÀÔ´Ï´Ù. ¹Ì±¹ º¸°Çº¹ÁöºÎ(HSS)¿Í º¸°ÇÀÚ¿ø¼ºñ½º±¹(HRSA)¿¡ µû¸£¸é, ¹Ì±¹ÀÇ °¢ ÁÖ´Â ½Å»ý¾Æ ½ºÅ©¸®´×ÀÇ ¹ýÀû ¿ä°Ç ¸ñ·ÏÀ» ¼ÒÀ¯Çϰí ÀÖ½À´Ï´Ù.
¹ýÀÇÇÐ µ¶¹°Çп¡¼ DBS äÃë Ä«µåÀÇ Ã¤¿ëÀÌ È®´ëµÇ°í ½Å»ý¾Æ ½ºÅ©¸®´×¿¡¼ÀÇ »ç¿ëÀÌ Áõ°¡Çϰí Àֱ⠶§¹®¿¡ ÀÌ ±ÍÁßÇÑ Áø´Ü µµ±¸ÀÇ ¹üÀ§°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ Ä«µå´Â ½Ã·á äÃëÀÇ ¿ëÀ̼º, ÀúÀå ¾ÈÁ¤¼º, ºñ¿ë È¿°ú µî ¸î °¡Áö ÀåÁ¡ÀÌ ÀÖ½À´Ï´Ù. ¹ýÀÇÇÐ µ¶¹°Çп¡¼ DBS Ä«µå´Â °³ÀÎÀ¸·ÎºÎÅÍ ¾à¹°, ¾ËÄÚ¿Ã ¹× µ¶¼Ò¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ ¹°ÁúÀ» È¿À²ÀûÀ¸·Î °¨ÁöÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Á¤º¸´Â Á×À½ÀÇ ¿øÀΰú ÀáÀçÀûÀÎ ¹üÁËÀÚÀÇ ½Äº°¿¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.
½Å»ý¾Æ ½ºÅ©¸®´×¿¡¼ DBS Ä«µå´Â À¯Àü¼º ¹× ´ë»ç¼º ÁúȯÀÇ Á¶±â ¹ß°ßÀ» ¿ëÀÌÇÏ°Ô Çϰí Àû½Ã °³ÀÔ°ú À¯¾ÆÀÇ °Ç° »óŸ¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¬±¸°¡ ÁøÇàµÇ°í ºÐ¼® ±â¼úÀÌ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ ºÐ¾ß¿¡¼ DBS Ä«µåÀÇ »ç¿ëÀÌ ´õ¿í È®´ëµÇ°í, ¹ýÀÇÇÐ ¼ö»ç¿Í ½Å»ý¾Æ °Ç° °ü¸®¿¡ ÇýÅÃÀ» ÁÖ°í ½ÃÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¹Ì±¹ÀÇ °ÇÁ¶ Ç÷¾× ½ºÆÌ äÃë Ä«µå ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- ¿ëµµº°·Î´Â ½Å»ý¾Æ ½ºÅ©¸®´× ºÐ¾ß°¡ 2023³â¿¡ 23.19%ÀÇ ÃÖ´ë ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇÏ°í ¿¹Ãø ±â°£ µ¿¾È CAGR 3.3%ÀÇ ´ëÆøÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ÀÌ ¼ºÀåÀº ¹Ì±¹¿¡¼ ½Å»ý¾Æ ½ºÅ©¸®´×ÀÇ ¼ö°¡ ¸¹±â ¶§¹®ÀÔ´Ï´Ù.
- Ä«µå À¯Çüº°·Î, Whatman 903 ºÎ¹®Àº 2023³â¿¡ 32.33%ÀÇ ÃÖ´ë ¼öÀÍ Á¡À¯À²·Î ½ÃÀåÀ» µ¶Á¡ÇÏ°í ¿¹Ãø ±â°£À» ÅëÇØ °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
- ÃÖÁ¾ ¿ëµµº°·Î´Â º´¿ø ¹× Áø·á¼Ò ºÎ¹®ÀÌ 2023³â¿¡ ÃÖ´ëÀÇ ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ CAGRÀ» ³ªÅ¸³»´Â °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ¹Ì±¹ÀÇ °ÇÁ¶ Ç÷¾× ½ºÆÌ äÃë Ä«µå ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óÀ§ ½ÃÀå Àü¸Á
- °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå °ßÀÎ ¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ¹Ì±¹ÀÇ °ÇÁ¶ Ç÷¾× ½ºÆý äÃë Ä«µå ½ÃÀå ºÐ¼® Åø
- ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå ¹Ì±¹ÀÇ °ÇÁ¶ Ç÷¾× ½ºÆý äÃë Ä«µå ½ÃÀå : ¿ëµµÀÇ ÃßÁ¤ ¹× µ¿Ç⠺м®
- ¿ëµµ ½ÃÀå Á¡À¯À², 2023³â ¹× 2030³â
- ºÎ¹® ´ë½Ãº¸µå
- ¹Ì±¹ÀÇ °ÇÁ¶ Ç÷¾× ½ºÆý äÃë Ä«µå ½ÃÀå, ¿ëµµº° Àü¸Á
- 2018³âºÎÅÍ 2030³â±îÁö ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®
- ½Å»ý¾Æ ½ºÅ©¸®´×
- °¨¿°Áõ °Ë»ç
- Ä¡·áÁ¦ ¸ð´ÏÅ͸µ
- ¹ýÀÇÇÐ
- CRO/¿¬±¸
- ±âŸ ¿ëµµ
Á¦5Àå ¹Ì±¹ÀÇ °ÇÁ¶ Ç÷¾× ½ºÆý äÃë Ä«µå ½ÃÀå : Ä«µå À¯ÇüÀÇ ÃßÁ¤ ¹× µ¿Ç⠺м®
- Ä«µå À¯Çü ½ÃÀå Á¡À¯À²: 2023³â°ú 2030³â
- ºÎ¹® ´ë½Ãº¸µå
- ¹Ì±¹ÀÇ °ÇÁ¶ Ç÷¾× ½ºÆý äÃë Ä«µå ½ÃÀå, Ä«µå À¯Çüº° Àü¸Á
- 2018³âºÎÅÍ 2030³â±îÁö ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®
- Whatman 903
- Ahlstrom 226
- FTA
- ±âŸ
Á¦6Àå ¹Ì±¹ÀÇ °ÇÁ¶ Ç÷¾× ½ºÆý äÃë Ä«µå ½ÃÀå : ÃÖÁ¾ ¿ëµµÀÇ ÃßÁ¤ ¹× µ¿Ç⠺м®
- ÃÖÁ¾ ¿ëµµ ½ÃÀå Á¡À¯À², 2023³â ¹× 2030³â
- ºÎ¹® ´ë½Ãº¸µå
- ÃÖÁ¾ ¿ëµµº° Àü¸Á¿¡ ÀÇÇÑ ¹Ì±¹ÀÇ °ÇÁ¶ Ç÷¾× ½ºÆý äÃë Ä«µå ½ÃÀå
- 2018³âºÎÅÍ 2030³â±îÁö ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®
- º´¿ø ¹× Ŭ¸®´Ð
- Áø´Ü¼¾ÅÍ
- ±âŸ
Á¦7Àå ¹Ì±¹ÀÇ °ÇÁ¶ Ç÷¾× ½ºÆý äÃë Ä«µå ½ÃÀå :Áö¿ª ÃßÁ¤ ¹× µ¿Ç⠺м®
- Áö¿ªº° ½ÃÀå Á¡À¯À², 2023³â ¹× 2030³â
- ºÎ¹® ´ë½Ãº¸µå
- Áö¿ªº° Àü¸Á¿¡ ÀÇÇÑ ¹Ì±¹ÀÇ °ÇÁ¶ Ç÷¾× ½ºÆý äÃë Ä«µå ½ÃÀå
- 2018-2030³â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®
- ¼ºÎ
- Áß¼ºÎ
- ºÏµ¿ºÎ
- ³²¼ºÎ
- ³²µ¿ºÎ
Á¦8Àå °æÀï ±¸µµ
- ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷¿¡ ÀÇÇÑ ÃÖ±ÙÀÇ µ¿Çâ°ú ¿µÇ⠺м®
- ±â¾÷/°æÀïÀÇ ºÐ·ù
- º¥´õ »óȲ
- ±â¾÷ ÇÁ·ÎÆÄÀÏ
- Whatman plc(Cytiva)
- GE Healthcare
- MilliporeSigma
- QIAGEN LLC
- PerkinElmer
- Roche
- Shimadzu Corporation
- Ahlstrom-Munksjo
- Eastern Business Forms, Inc.
- CENTOGENE NV
JHS
¿µ¹® ¸ñÂ÷
U.S. Dried Blood Spot Collection Cards Market Growth & Trends:
The U.S. dried blood spot collection cards market size is anticipated to reach USD 149.9 million by 2030, growing at a CAGR of 3.9% during the forecast period, according to a new report by Grand View Research, Inc. The rising application in newborn screening and expanding utilization of DBS cards in forensic toxicology are significant factors contributing to the market growth. According to the U.S. Department of Health & Human Services (HSS) and Health Resources & Services Administration (HRSA), each state of the U.S. possesses its legal list of requirements for screening newborns.
The growing adoption of dried blood spot collection cards in forensic toxicology and their increasing use in newborn screening is expanding the scope of these valuable diagnostic tools. These cards offer several advantages, such as ease of sample collection, storage stability, and cost-effectiveness. In forensic toxicology, DBS cards enable efficient detection of various substances, including drugs, alcohol, and toxins, in individuals. This information is crucial for determining the cause of death and identifying potential criminals.
In newborn screening, DBS cards facilitate early detection of genetic disorders and metabolic diseases, allowing for timely interventions and improved health outcomes for infants. As research progresses and analytical techniques continue to advance, the utilization of DBS cards in these fields is expected to expand further, benefiting forensic investigations and newborn healthcare, and contributing to the market.
U.S. Dried Blood Spot Collection Cards Market Report Highlights:
- Based on application, the newborn screening segment held the largest revenue share of 23.19% in 2023 and is expected to grow at a significant CAGR of 3.3% during the forecast period. The growth is attributed to the larger number of newborn screenings in the U.S.
- Based in card type, the Whatman 903 segment dominated the market with the largest revenue share of 32.33% in 2023 and is expected to grow at the fastest CAGR throughout the forecast period
- Based on end-use, the hospitals & clinics segment accounted for the largest revenue share in 2023. The segment is expected to exhibit a lucrative CAGR over the forecast period
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Application
- 1.2.2. Card Type
- 1.2.3. End-use
- 1.2.4. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Volume price analysis (Model 2)
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Application outlook
- 2.2.2. Card Type outlook
- 2.2.3. End-use outlook
- 2.3. Competitive Insights
Chapter 3. U.S. Dried Blood Spot Collection Cards Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.3. U.S. Dried Blood Spot Collection Cards Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
Chapter 4. U.S. Dried Blood Spot Collection Cards Market: Application Estimates & Trend Analysis
- 4.1. Application Market Share, 2023 & 2030
- 4.2. Segment Dashboard
- 4.3. U.S. Dried Blood Spot Collection Cards Market by Application Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.4.1. Newborn Screening (NBS)
- 4.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.2. Infectious Diseases Testing
- 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.3. Therapeutic Drug Monitoring
- 4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.4. Forensics
- 4.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.5. CRO/Research
- 4.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.6. Other Applications
- 4.4.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 5. U.S. Dried Blood Spot Collection Cards Market: Card Type Estimates & Trend Analysis
- 5.1. Card Type Market Share, 2023 & 2030
- 5.2. Segment Dashboard
- 5.3. U.S. Dried Blood Spot Collection Cards Market by Card Type Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.4.1. Whatman 903
- 5.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 5.4.2. Ahlstrom 226
- 5.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 5.4.3. FTA
- 5.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 5.4.4. Others
- 5.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 6. U.S. Dried Blood Spot Collection Cards Market: End-use Estimates & Trend Analysis
- 6.1. End-use Market Share, 2023 & 2030
- 6.2. Segment Dashboard
- 6.3. U.S. Dried Blood Spot Collection Cards Market by End-use Outlook
- 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.4.1. Hospitals & Clinics
- 6.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 6.4.2. Diagnostics Centers
- 6.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 6.4.3. Others
- 6.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 7. U.S. Dried Blood Spot Collection Cards Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share, 2023 & 2030
- 7.2. Segment Dashboard
- 7.3. U.S. Dried Blood Spot Collection Cards Market by Regional Outlook
- 7.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the Following
- 7.4.1. West
- 7.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 7.4.2. Midwest
- 7.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 7.4.3. Northeast
- 7.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 7.4.4. Southwest
- 7.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 7.4.5. Southeast
- 7.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. List of key distributors and channel partners
- 8.3.2. Key customers
- 8.3.3. Key company heat map analysis, 2023
- 8.4. Company Profiles
- 8.4.1. Whatman plc (Cytiva)
- 8.4.1.1. Company overview
- 8.4.1.2. Financial performance
- 8.4.1.3. Product benchmarking
- 8.4.1.4. Strategic initiatives
- 8.4.2. GE Healthcare
- 8.4.2.1. Company overview
- 8.4.2.2. Financial performance
- 8.4.2.3. Product benchmarking
- 8.4.2.4. Strategic initiatives
- 8.4.3. MilliporeSigma
- 8.4.3.1. Company overview
- 8.4.3.2. Financial performance
- 8.4.3.3. Product benchmarking
- 8.4.3.4. Strategic initiatives
- 8.4.4. QIAGEN LLC
- 8.4.4.1. Company overview
- 8.4.4.2. Financial performance
- 8.4.4.3. Product benchmarking
- 8.4.4.4. Strategic initiatives
- 8.4.5. PerkinElmer
- 8.4.5.1. Company overview
- 8.4.5.2. Financial performance
- 8.4.5.3. Product benchmarking
- 8.4.5.4. Strategic initiatives
- 8.4.6. Roche
- 8.4.6.1. Company overview
- 8.4.6.2. Financial performance
- 8.4.6.3. Product benchmarking
- 8.4.6.4. Strategic initiatives
- 8.4.7. Shimadzu Corporation
- 8.4.7.1. Company overview
- 8.4.7.2. Financial performance
- 8.4.7.3. Product benchmarking
- 8.4.7.4. Strategic initiatives
- 8.4.8. Ahlstrom-Munksjo
- 8.4.8.1. Company overview
- 8.4.8.2. Financial performance
- 8.4.8.3. Product benchmarking
- 8.4.8.4. Strategic initiatives
- 8.4.9. Eastern Business Forms, Inc.
- 8.4.9.1. Company overview
- 8.4.9.2. Financial performance
- 8.4.9.3. Product benchmarking
- 8.4.9.4. Strategic initiatives
- 8.4.10. CENTOGENE N.V.
- 8.4.10.1. Company overview
- 8.4.10.2. Financial performance
- 8.4.10.3. Product benchmarking
- 8.4.10.4. Strategic initiatives
°ü·ÃÀÚ·á